euro adhoc: Sygnis Pharma AG
SYGNIS announces successful completion of the clinical IIa study for AX200 in stroke (AXIS)

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Research & Development


Heidelberg, July 22nd, 2007 -  SYGNIS Pharma AG has successfully completed the clinical phase IIa-study (AXIS) in stroke. AXIS was a multicenter, doubleblind, placebo-controlled dose escalation study. The comprehensive analysis of the study data showed that the primary and secondary endpoints have been achieved and that the use of AX200 in stroke patients can be considered to be safe.

Although the focus of the AXIS-study was the collection of data regarding safety and tolerability, data regarding the efficacy of AX200 were also monitored. Due to the small number of patients involved in such a safety study, a significant difference between AX200 and placebo treated patients could not be observed in the overall consideration of the usual clinical endpoints. However, a detailed statistical evaluation of the data provided hints that certain stroke patients may benefit from a treatment with AX200.

AX200 for the treatment of acute stroke is the most advanced drug candidate in SYGNIS´ product pipeline. Besides stroke, SYGNIS is currently preclinically testing the endogenous protein AX200 in further neurodegenerative indications such as Amyotrophic Lateral Sclerosis (ALS).

With the positive results of the AXIS study the path has been cleared for the further clinical development of AX200. SYGNIS is now in the process of designing and preparing the phase IIb trial whose aim will be to demonstrate the efficacy of AX200 in stroke patients.

###Except for the historical information contained herein, the matters set forth in this press release are forward looking. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on SYGNIS´ current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of SYGNIS to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. ###

@@start.t2@@end of announcement                                                 euro adhoc 22.07.2007 15:41:40

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Franz-Werner Haas
Vice President Operations
Telefon: +49(0)6221 454-812

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse Hannover / free trade
              Börse München / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: